The therapeutic response of approved KRAS inhibitors is not always durable and patients develop resistance frequently. To enhance this durability, the search for KRAS inhibitors in combination with drugs that target downstream or upstream components of RAS is crucial.
Nippon Shinyaku Co. Ltd. has patented discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, hepatic and pulmonary fibrosis, myelofibrosis, nephritis, osteoarthritis and chronic renal failure.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Philochem AG has discovered an ultra-high-affinity ACP3 ligand – OncoACP3 – isolated through the screening of DNA-encoded chemical libraries for the potential treatment of prostate cancer.
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.
Bright Peak Therapeutics Inc. has raised $90 million in a series C financing. Proceeds will be used to accelerate a pipeline of next-generation immunotherapies and advance BPT-567 into a phase I/IIa trial.
Work at Open Source Therapeutics has led to the preparation of pyridone compounds acting as phosphodiesterase PDE3A/SLFN12 interaction inducers reported to be useful for the treatment of cancer.
Incyte Corp. has patented heteroaryl fluoroalkenes acting as diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors and thus reported to be useful for the treatment of cancer.
Calidi Biotherapeutics Inc. has conducted studies in animals to determine the safety and efficacy of oncolytic virotherapy (OV) with CLD-201 (Supernova-1) to treat solid tumors.
RSS
